In addition, taking into consideration that PDS was an easily accessible indicator, it may also valuable in monitoring the treatment response of metastatic disease to systemic therapies like CEA [73]; however, more studies are needed to validate its role in such a scenario. The gene discussed is CEACAM5; the disease is metastatic neoplasm.